Diagnostics: Page 2
-
Spencer Platt via Getty Images
AI’s expert-level image analysis can be built on flawed rationales: study
Researchers at the National Institutes of Health found that a version of ChatGPT analyzed images at an expert level but frequently reached the right answer with incorrect reasoning.
By Nick Paul Taylor • July 25, 2024 -
Courtesy of Business Wire
Guardant settles allegations it violated the False Claims Act
The settlement resolves claims that an oncologist ordered significantly more tests after Guardant hired two people the physician recommended for jobs at the company.
By Nick Paul Taylor • July 23, 2024 -
Explore the Trendline➔
Sitthiphong via Getty Images
TrendlineMedical device industry continues to turn to AI
While the industry continues to embrace artificial intelligence, there are still questions about how the new technologies need to be regulated and if they are effective.
By MedTech Dive staff -
Courtesy of Truvian
Truvian raises $74M to bring blood test instrument to market
The device is designed to perform the most commonly ordered blood tests, avoiding the need to send the samples to central labs.
By Nick Paul Taylor • July 22, 2024 -
Permission granted by Medtronic
Q&A‘Our next frontier is prediction’: Medtronic on AI and heart disease
Stacey Churchwell, who leads the company’s cardiovascular diagnostics and services business, says artificial intelligence is reducing false positives in its insertable cardiac monitors, saving clinicians valuable time.
By Susan Kelly • July 22, 2024 -
deliormanli via Getty Images
Danaher setting up labs to support companion diagnostic development
Danaher plans to open a U.K. laboratory this month, followed by a second facility in the U.S. later this year.
By Nick Paul Taylor • July 18, 2024 -
Ryan David Brown/Getty Images via Getty Images
Deep DiveMedtech firms have cut more than 14,000 jobs in the past 18 months
Diagnostics is the largest industry represented in the data, with more than 5,000 affected positions, according to MedTech Dive’s analysis.
By Jasmine Ye Han , Ricky Zipp , Elise Reuter • Updated July 25, 2024 -
Courtesy of Qiagen
Qiagen to cut 175 employees, close Michigan PCR test plant
The layoffs and plant closure are part of a restructuring plan that Qiagen estimates will cost about $400 million.
By Elise Reuter • July 17, 2024 -
Courtesy of Quest Diagnostics
Quest closing Pennsylvania lab, laying off 121 people
Quest is consolidating drug testing at a facility in Kansas, but will keep rapid response, pathology and IT staff at the Norristown site.
By Nick Paul Taylor • July 17, 2024 -
Courtesy of Intuitive Surgical
J&J, Abbott and Intuitive start medtech earnings season
The companies’ financial results will offer a glimpse at the current health of medtech markets.
By Nick Paul Taylor • July 16, 2024 -
Jemal Countess via Getty Images
House committee tells FDA to suspend lab developed test rule
Lawmakers said the final rule carries “the risk of greatly altering the United States’ laboratory testing infrastructure.”
By Nick Paul Taylor • July 15, 2024 -
Anna Moneymaker / Staff via Getty Images
Deep DiveFDA’s lab developed test rule could be first check on agency’s power post-Chevron
The Supreme Court’s decision to overturn the Chevron doctrine would make it easier to challenge agency regulations, such as the LDT final rule.
By Susan Kelly , Elise Reuter • July 11, 2024 -
Courtesy of BD
FDA warns BD blood culture bottle shortage could impact diagnosis
BD said reduced availability of blood culture media bottles due to supplier issues has prevented it from meeting global demand.
By Nick Paul Taylor • July 11, 2024 -
Courtesy of Quest Diagnostics
Quest to buy Lifelabs for $985M
Buying the Canadian laboratory company opens a new front in Quest’s rivalry with Labcorp and marks its third takeover in as many months.
By Nick Paul Taylor • July 8, 2024 -
Courtesy of Roche
Roche sues Foresight and Stanford, alleging use of trade secrets
Roche said Stanford applied for patents relating to cancer detection and monitoring technology using its confidential information.
By Nick Paul Taylor • July 3, 2024 -
Courtesy of U.S. Food and Drug Administration
Cepheid wins FDA nod for fingerstick hepatitis C test
Patients could be diagnosed and potentially receive treatment at the same healthcare visit.
By Nick Paul Taylor • June 28, 2024 -
David Ryder via Getty Images
FDA partners with Gates Foundation to support breath-based diagnostic development
Through a $1.9 million Gates Foundation grant, the collaborators will create methods to help developers make tests that can easily be deployed to rural and remote areas.
By Nick Paul Taylor • June 27, 2024 -
Courtesy of Grail
Illumina completes Grail spinoff
Nearly four years after Illumina announced a deal to buy Grail, the liquid biopsy maker will debut on Nasdaq Tuesday as a standalone company.
By Nick Paul Taylor • June 25, 2024 -
Retrieved from Dermtech on June 20, 2024
Dermtech files for Chapter 11, lays off 20% of staff
The diagnostic test maker will continue to hunt for a buyer for its skin cancer detection patch.
By Nick Paul Taylor • June 20, 2024 -
Permission granted by Agilent
Agilent to cut 3% of employees as sluggish lab equipment market persists
An Agilent spokesperson said the layoffs follow job cuts announced late last year amid a slower-than-expected market recovery.
By Susan Kelly • June 14, 2024 -
Permission granted by Danaher
Danaher names Martin Stumpe as chief data and AI officer
Martin Stumpe will take over the new position after previously working as Tempus’ chief of AI and the head of Google’s pathology team.
By Nick Paul Taylor • June 6, 2024 -
Dr_Microbe via Getty Images
Saliva test identifies men at high risk of prostate cancer
Data presented at the American Society of Clinical Oncology meeting suggest the test can support prostate cancer diagnosis in people who are missed by other screening methods.
By Nick Paul Taylor • June 5, 2024 -
Courtesy of Grail
Illumina board approves Grail spinoff
Leerink Partners analyst Puneet Souda said Grail, with a cash burn of $532 million in 2023, is likely to remain “a cautionary tale in diagnostics for years to come.”
By Susan Kelly • June 4, 2024 -
Courtesy of Illumina
Illumina names Everett Cunningham as chief commercial officer
Cunningham will join Illumina from Exact Sciences to end the six-month search for a permanent leader.
By Nick Paul Taylor • June 4, 2024 -
K-Kwanchai via Getty Images
Lab industry sues to stop FDA’s new LDT rule
The American Clinical Laboratory Association argues the agency does not have the authority to enforce stricter standards on lab developed tests.
By Susan Kelly • May 30, 2024 -
Courtesy of GuardantHealth
FDA panel backs Guardant’s blood test for colon cancer
“The favorable panel vote does not by any means imply this test will become an overnight success,” wrote William Blair analyst Andrew Brackmann.
By Susan Kelly • May 24, 2024
Previous
